BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:00 PM
 | 
Jun 30, 2008
 |  BC Extra  |  Company News

Pfizer, Derbyshire PCT unveil AMD drug appeals

Pfizer (NYSE:PFE) and the Derbyshire County Primary Care Trust on Monday unveiled details of their appeals against preliminary recommendations by the U.K.'s NICE regarding the use of Macugen pegaptanib and Lucentis ranibizumab to treat wet age-related macular degeneration (AMD). In December, NICE said it planned to not recommend Pfizer's Macugen while recommending...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >